ProMIS Neurosciences
Tuesday, February 27, 2024
Plymouth
CNS/Neurological
ProMIS Neurosciences (Nasdaq:PMN) is a Cambridge, Massachusetts and Toronto, Ontario-based clinical stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. Using our proprietary target discovery engine, we can predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
State
MA
Country
United States
Website
https://www.promisneurosciences.com/
CEO/Top Company Official
Neil Warma
Lead Product in Development
PMN310, a novel Antibody currently in Phase 1 for the treatment of Alzheimer's disease
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
3-4
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}